Ontology type: schema:ScholarlyArticle
2008-05
AUTHORSBrian R. Leaker, B. O’Connor, Trevor T. Hansel, Peter J. Barnes, Lixen Meng, Vandana S. Mathur, Hsiao D. Lieu
ABSTRACTBACKGROUND: Patients with reactive airways are at risk for adenosine-induced bronchoconstriction, mediated via A(2B) and/or A(3) adenosine receptors. METHODS AND RESULTS: To examine the effects of regadenoson, a selective adenosine A(2A) receptor agonist, on airway resistance, we conducted a randomized, double-blind, placebo-controlled crossover trial in asthmatic patients with a positive adenosine monophosphate challenge test. The mean ratio of the forced expiratory volume in 1 second (FEV(1)) at each tested time point relative to the baseline FEV(1) was significantly higher after treatment with regadenoson compared with placebo from 10 to 60 minutes after treatment. One patient had a substantial but asymptomatic FEV(1) reduction (-36.2%) after regadenoson that reversed spontaneously. The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%). The mean heart rate significantly increased with regadenoson (maximum of +10.4 beats/min) versus placebo. CONCLUSIONS: In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated. More... »
PAGES329-336
http://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009
DOIhttp://dx.doi.org/10.1016/j.nuclcard.2008.02.009
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1037812905
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/18513639
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adenosine A2 Receptor Antagonists",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Asthma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Coronary Artery Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Double-Blind Method",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Exercise Test",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pilot Projects",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Placebo Effect",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Purines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyrazoles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Respiration Disorders",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risk Assessment",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risk Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"name": [
"From the Pulmonology, Heart and Lung Centre, London, England"
],
"type": "Organization"
},
"familyName": "Leaker",
"givenName": "Brian R.",
"id": "sg:person.01327066420.63",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327066420.63"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"From the Pulmonology, Heart and Lung Centre, London, England"
],
"type": "Organization"
},
"familyName": "O\u2019Connor",
"givenName": "B.",
"id": "sg:person.01012400567.25",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012400567.25"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"From the Pulmonology, Heart and Lung Centre, London, England"
],
"type": "Organization"
},
"familyName": "Hansel",
"givenName": "Trevor T.",
"id": "sg:person.01311065707.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311065707.38"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"From the Pulmonology, Heart and Lung Centre, London, England"
],
"type": "Organization"
},
"familyName": "Barnes",
"givenName": "Peter J.",
"id": "sg:person.01045564377.55",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045564377.55"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Gilead Sciences (United States)",
"id": "https://www.grid.ac/institutes/grid.418227.a",
"name": [
"Biostatistics, CV Therapeutics, Palo Alto, Calif."
],
"type": "Organization"
},
"familyName": "Meng",
"givenName": "Lixen",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Gilead Sciences (United States)",
"id": "https://www.grid.ac/institutes/grid.418227.a",
"name": [
"Clinical Research, CV Therapeutics, Palo Alto, Calif."
],
"type": "Organization"
},
"familyName": "Mathur",
"givenName": "Vandana S.",
"id": "sg:person.01077014765.45",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077014765.45"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Gilead Sciences (United States)",
"id": "https://www.grid.ac/institutes/grid.418227.a",
"name": [
"Clinical Research, CV Therapeutics, Palo Alto, Calif."
],
"type": "Organization"
},
"familyName": "Lieu",
"givenName": "Hsiao D.",
"id": "sg:person.0654506263.79",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654506263.79"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/s0140-6736(98)10019-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009352689"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1067/mhj.2001.116070",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012604102"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0735-6757(93)90138-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016818117"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0165-6147(98)01179-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017804473"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.jcmg.2008.02.003",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1021315962"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1378/chest.127.6.2222",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024504709"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0735-1097(94)90424-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025970600"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00003088-200645120-00005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027091187",
"https://doi.org/10.2165/00003088-200645120-00005"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00003088-200645120-00005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027091187",
"https://doi.org/10.2165/00003088-200645120-00005"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1378/chest.89.3.335",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040848762"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/(sici)1098-2299(199611/12)39:3/4<333::aid-ddr14>3.0.co;2-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042024088"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1152/ajplung.00353.2002",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1063195609"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1177/096032719401300407",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1063901801"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1177/096032719401300407",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1063901801"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1378/chest.106.4.1083",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1067171984"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.4049/jimmunol.172.12.7726",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1076850170"
],
"type": "CreativeWork"
}
],
"datePublished": "2008-05",
"datePublishedReg": "2008-05-01",
"description": "BACKGROUND: Patients with reactive airways are at risk for adenosine-induced bronchoconstriction, mediated via A(2B) and/or A(3) adenosine receptors.\nMETHODS AND RESULTS: To examine the effects of regadenoson, a selective adenosine A(2A) receptor agonist, on airway resistance, we conducted a randomized, double-blind, placebo-controlled crossover trial in asthmatic patients with a positive adenosine monophosphate challenge test. The mean ratio of the forced expiratory volume in 1 second (FEV(1)) at each tested time point relative to the baseline FEV(1) was significantly higher after treatment with regadenoson compared with placebo from 10 to 60 minutes after treatment. One patient had a substantial but asymptomatic FEV(1) reduction (-36.2%) after regadenoson that reversed spontaneously. The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%). The mean heart rate significantly increased with regadenoson (maximum of +10.4 beats/min) versus placebo.\nCONCLUSIONS: In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated.",
"genre": "research_article",
"id": "sg:pub.10.1016/j.nuclcard.2008.02.009",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1106202",
"issn": [
"1071-3581",
"1532-6551"
],
"name": "Journal of Nuclear Cardiology",
"type": "Periodical"
},
{
"issueNumber": "3",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "15"
}
],
"name": "Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial",
"pagination": "329-336",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"b4216bd02a858e25d9ea2a18794758823d7b942ca396ec5135546fe4b82a0777"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"18513639"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"9423534"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1016/j.nuclcard.2008.02.009"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1037812905"
]
}
],
"sameAs": [
"https://doi.org/10.1016/j.nuclcard.2008.02.009",
"https://app.dimensions.ai/details/publication/pub.1037812905"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T23:30",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000537.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1016%2Fj.nuclcard.2008.02.009"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'
This table displays all metadata directly associated to this object as RDF triples.
234 TRIPLES
21 PREDICATES
61 URIs
39 LITERALS
27 BLANK NODES